Nemolizumab is an interleukin-31 receptor alpha antagonist used to treat prurigo nodularis in adults. Nemolizumab is a humanized monoclonal modified immunoglobulin 2 (IgG2) antibody directed against interleukin-31 receptor alpha (IL-31RA), which is an endogenous cytokine implicated in the pathophysiology of various skin inflammatory disorders.
- Mechanism
- Curator reviewed · 7 references
Interleukin-31 (IL-31) is a cytokine involved in neuroimmune communication. It is identified as one of the key drivers in inflammatory and immune conditions, such as pruritus, inflammation, epidermal dysregulation, and fibrosis. The release of IL-31 is stimulated by T helper 2 (TH2) cells to mediate pro-inflammatory responses. IL-31 signals through a heterodimeric receptor complex consisting of IL-31 receptor alpha (α)-chain (IL-31RA) and oncostatin M receptor beta (β). Nemolizumab is a humanized IgG2 monoclonal antibody that inhibits IL-31 signalling by binding selectively to IL-31RA. Nemolizumab inhibits IL-31-induced responses, including the release of proinflammatory cytokines and chemokines.
- Primary indication
- Nemolizumab is indicated for the treatment of adults with prurigo nodularis.Curator reviewed · 1 structured indication
- Formula / weight
- C6384H9814N1678O2034S48 · 144000.0 Da (approximate)
- First approval
- Canada, 2025 · United States, 2024 · European Union, 2025
- Also known as
- immunoglobulin G2-kappa, anti-[Homo sapiens IL31RA (interleukin 31 receptor subunit alpha)], humanized monoclonal antibody gamma2 heavy chain (1-445) [humanized VH (Homo sapiens IGHV1-2*02 (83.70%) -(IGHD)-IGHJ5*01) [8.8.14] (1-121) -Homo sapiens IGHG2*0 · Immunoglobulin G2, anti-(interleukin 31 receptor A) (human-Mus musculus monoclonal CIM331 γ-chain), disulfide with human-Mus musculus monoclonal CIM331 κ-chain, dimer
- Code names
- CD14152 · CIM-331
- Brand names
Resolves to
What you can answer from here — as of May 26, 2026
Which drugs share a target with Nemolizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account